Completed

CBD for Neuropathic Pain in Diabetic Foot Neuropathy

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Group 1. Complete formula

+ Group 2. Cannabidiol and Urea 10% formula.

+ Group 3. Placebo formula.

Drug
Who is being recruted

Cardiovascular Diseases+21

+ Diabetes Mellitus

+ Diabetic Angiopathies

Over 18 Years
+8 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Placebo-Controlled
Interventional
Study Start: November 2024
See protocol details

Summary

Principal SponsorUniversidad Complutense de Madrid
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: November 1, 2024

Actual date on which the first participant was enrolled.

This clinical study focuses on examining how cannabidiol (CBD), a compound derived from cannabis, can help reduce neuropathic pain in individuals suffering from diabetic foot neuropathy. This condition often causes severe pain and discomfort due to nerve damage associated with diabetes. The study aims to provide insights into whether CBD can be an effective treatment option for managing this type of pain, which could lead to better quality of life for those affected by diabetic foot syndrome. Additionally, the study looks at how using urea 10% cream might improve the skin quality of patients with this condition. Participants in the study receive treatments to assess their effects on neuropathic pain and skin health. The CBD is administered to see how it influences pain levels, while the urea 10% cream is applied to evaluate any improvements in the skin's condition. The study is designed to ensure neither the participants nor the researchers know who receives the actual treatment or a placebo, making it triple-blind. This helps ensure unbiased results. While the study does not specify the exact method of CBD administration, such studies typically involve oral or topical forms. The research does not explicitly mention risks or benefits, but the potential to alleviate pain and improve skin health is a significant focus.

Official TitleA Triple-Blind Randomised Clinical Trial on the Effectiveness of CBD for Neuropathic Pain in Diabetic Foot Neuropathy
NCT07162454
Principal SponsorUniversidad Complutense de Madrid
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

23 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Cardiovascular DiseasesDiabetes MellitusDiabetic AngiopathiesDiabetic NeuropathiesEndocrine System DiseasesLeg UlcerMetabolic DiseasesNervous System DiseasesNeuralgiaNeurologic ManifestationsNeuromuscular DiseasesNutritional and Metabolic DiseasesPainPeripheral Nervous System DiseasesSigns and SymptomsSkin DiseasesSkin UlcerPathological Conditions, Signs and SymptomsVascular DiseasesFoot UlcerSkin and Connective Tissue DiseasesDiabetic FootGlucose Metabolism DisordersDiabetes Complications

Criteria

5 inclusion criteria required to participate
Patients all biological sexes

Patients of legal age (18 years).

Patients without cognitive impairment

Patients Diagnosed with diabetic neuropathy,

Show More Criteria

3 exclusion criteria prevent from participating
Patients who declined participation

Patients with critical ischaemia and

Patients with a history of allergy or hypersensitivity to any of the components of the cream were excluded from the study.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

3 intervention groups are designated in this study

33.333% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
Participants in this group received a cream with cannabidiol, urea 10%, arnica and menthol as active ingredients during 1 month.

Group II

Experimental
Participants in this group received a cream with cannabidiol, urea 10% as active ingredients during 1 month.

Group III

Placebo
Participants in this group received a base cream with no active ingredients.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Facultad de Enfermería, Fisioterapia y Podología de la Universidad Complutense de Madrid

Madrid, SpainOpen Facultad de Enfermería, Fisioterapia y Podología de la Universidad Complutense de Madrid in Google Maps
CompletedOne Study Center